NCT06752538

Brief Summary

While robotic gastrectomy (RG) is increasingly used in gastric cancer surgery, its potential advantages over laparoscopic gastrectomy (LG) in Intraoperative technical complexity (ITC) cases remain debated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,534

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2016

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
5.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 30, 2024

Completed
Last Updated

June 11, 2025

Status Verified

June 1, 2025

Enrollment Period

2.8 years

First QC Date

December 22, 2024

Last Update Submit

June 6, 2025

Conditions

Gastrectomy for Gastric CancerRobotic Surgical ProceduresLaparoscopic Surgical Procedures

Keywords

Surgical difficultyGastrectomyRoboticLaparoscopic

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    Telephone follow-up

    Within 3 years after surgery

Secondary Outcomes (2)

  • recurrence

    36 months

  • Postoperative complications

    30 days after surgery

Study Arms (2)

RG group

Patients undergoing robotic gastrectomy

LG group

Patients undergoing laparoscopic gastrectomy

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with pathologically confirmed T1-4aN0-3bM0 gastric adenocarcinoma who underwent radical RG or LG between August 2016 and June 2019 at eight high-volume tertiary teaching hospitals in China

You may qualify if:

  • Patients with postoperatively histologically confirmed T1-4aN0-3bM0 gastric adenocarcinoma who underwent RG or LG

You may not qualify if:

  • Remnant gastric cancer
  • Previous malignant
  • ASA class \>3
  • Use of indocyanine green
  • Neoadjuvant chemotherapy
  • Loss to follow-up
  • Combined resection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China

Location

Study Officials

  • Chang-Ming Huang, PhD

    Fujian Medical University Union Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 22, 2024

First Posted

December 30, 2024

Study Start

August 1, 2016

Primary Completion

June 1, 2019

Study Completion

July 1, 2024

Last Updated

June 11, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)